A lectina ArtinM, extraída de sementes de Artocarpus heterophyllus e caracterizada como um homotetrâmero constituído de subunidades de 16 kDa, tem alta afinidade de ligação a manotriose Man? 1-3 [Man? 1-6] Man, que constitui o core de N-glicanas. ArtinM é dotada de interessantes propriedades biológicas: (1) ativa neutrófilos a partir do reconhecimento de N-glicanas dos receptores CXCR2 e TLR2; (2) induz a desgranulação de mastócitos por interagir com N-glicanas de Fc?R ou com N-glicanas de IgE ligadas a Fc?R; (3) estimula a produção de IL-12, por reconhecer N-glicanas contidas no ectodomínio de TLR2 da superfície de células apresentadoras de antígeno (APCs); (4) exerce atividade imunomoduladora, que direciona o padrão de resposta para o perfil Th1; (5) confere resistência a infecções por patógenos intracelulares, como Paracoccidioides brasiliensis, Leishmania amazonensis e Leishmania major, Neospora caninum e Candida albicans Células T CD4+ participam de funções essenciais do sistema imune; durante o estabelecimento de uma resposta imune, podem ser desenvolvidas subpopulações de células T CD4+ adequadas para gerar respostas eficientes de combate a patógenos, manutenção da tolerância e regulação da imunidade. A ativação das células T CD4+ depende de um primeiro sinal, desencadeado pelo complexo TCR/CD3, e de um segundo sinal, oriundo de moléculas coestimulatórias como CD28. A ativação e expansão de células T CD4+ são limitadas pela ação de moléculas inibitórias, principalmente por CTLA-4. Lectinas podem ativar as células T, sendo a fitohemaglutinina (PHA) e a Concanavalin A (ConA) os exemplos mais conhecidos. Além disso, está bem caracterizado que o alvo de reconhecimento de ConA localiza-se no complexo TCR/CD3. No presente estudo buscou-se caracterizar os efeitos da lectina ArtinM sobre células T CD4+ murinas e investigar os possíveis mecanismos responsáveis pelos efeitos exercidos. Foram avaliados, inicialmente, os efeitos diretos de ArtinM sobre as células T CD4+, no que se refere à produção de citocinas, expressão de moléculas coestimulatórias e inibitórias e indução de diferenciação celular. Passou-se então à identificação de possíveis receptores de superfície reconhecidos por ArtinM e responsáveis pelo desencadeamento da ativação celular. Finalmente, buscou-se apontar moléculas sinalizadoras envolvidas nos efeitos diretos de ArtinM. A primeira evidência da interação direta de ArtinM com células T CD4+ foi proporcionada por aglutinação celular. Uma curva dose-resposta revelou que 5µg/ml foi a melhor concentração para adquirir significativa produção de citocinas Th1 (IL-2 e IFN-?) e Th17 (IL-6 e IL-17A) pelas células T CD4+. O estímulo com a concentração ótima de ArtinM mostrou que após 12 horas de incubação houve um significativo aumento nos níveis de IL-2, IFN-?, IL-6 e IL-17A no sobrenadante celular; persistindo no curso de 48 horas de observação. A secreção concomitante de IFN-? e IL-17A motivou a avaliação, por citometria de fluxo, da ocorrência de dupla marcação intracelular dessas citocinas. O estímulo, por 24 horas, com ArtinM, levou a importante aumento da frequência de células duplo-positivas para IFN-? e IL-17. Uma vez comprovado pelo padrão de citocinas secretadas que ArtinM promove a ativação das células T CD4+, investigou-se a expressão das moléculas CD25 e CTLA-4. ArtinM aumentou a expressão de ambas as moléculas, de maneira dose-dependente. Curiosamente, a detecção tanto de CD28, como de CTLA-4, foi precoce e persistente, diferindo do padrão temporal de expressão proporcionado por outros ativadores de células T CD4+. Com vistas a determinar o mecanismo através do qual ArtinM atua nas células T CD4+, alvos potenciais de reconhecimento foram ensaiados: CD3?, CD3??, CD28, CD45 e CD4. Esses receptores foram selecionados com base em predição de potenciais sítios Nglicosilados. Dessa forma, anticorpos específicos para essas moléculas foram utilizados para analisar a sua capacidade de inibir a atividade de ArtinM de induzir as células T CD4+ a produzir citocinas, como IL-2, IFN-?, IL-6 e IL-17A. Apenas o anticorpo anti-CD3?? foi capaz de impedir a secreção das citocinas induzidas por ArtinM. Além disso, esse anticorpo inibiu a marcação de células T CD4+ por ArtinM biotinilada. Esses dados indicam que ArtinM exerce sua atividade sobre células T CD4+ através do reconhecimento de glicanas na cadeia ? do receptor CD3, não excluindo-se, entretanto, a ocorrência da interação de ArtinM com outras glicoproteínas na superfície de linfócitos T CD4+. Também foi verificado que ArtinM possui alta especificidade por glicanas na superfície dessas células, pois foram necessárias elevadas concentrações de manotriose para inibir em 50% a ligação de ArtinM à superfície das células T CD4+. Através do uso de inibidores específicos para moléculas sinalizadoras, constatou-se que PI3K, PTK, p42/44MAPK, p38MAPK, JNK e PKC estão implicadas na sinalização para a produção das citocinas de perfis Th1 e Th17, induzida por ArtinM. Esse conjunto de resultados indica que ArtinM é um potente e rápido ativador de células T CD4+. A ativação celular induzida por ArtinM está relacionada com a ligação à cadeia ? do receptor CD3 e se associa à alta expressão de moléculas coestimuladoras e inibitórias. Ademais, demonstrou-se que ArtinM promove a diferenciação das células T CD4+ naive em células Th1 e Th17, utilizando moléculas sinalizadoras que são conhecidas como críticas para a indução de citocinas que caracterizam essas subpopulações celulares. / The lectin ArtinM, extracted from seeds of Artocarpus heterophyllus and characterized as a homotetramer consisted of 16 kDa subunits, has high binding affinity to the manotriose Man? 1-3 [Man? 1-6] Man, which is the core of N-glycans. ArtinM is endowed with interesting biological properties: (1) it activates neutrophils through the recognition of Nglycans attached to CXCR2 and TLR2 receptors; (2) induces degranulation of mast cells by interacting with N-glycans of Fc?R or to N-glycans of IgE bound to Fc?R; (3) stimulates the production of IL-12 through the recognition of N-glycans of the TLR2 ectodomain, expressed on the surface of antigen presenting cells (APCs); (4) exerts immunomodulatory activity, which accounts for Th1 immunity (5) confers resistance to intracellular pathogens, such as P. brasiliensis, Leishmania amazonensis and Leishmania major, Neospora caninum e Candida albicans. CD4+ T cells participate in essential functions of the immune system. During the development of an immune response, CD4+ T cells are activated and give origin to subpopulations of cells that are suitable for establishing effective responses to combat pathogens, for tolerance maintenance, and for adequate immuneregulation. The activation of CD4+ T cells depends on a first signal, triggered by the TCR/CD3 complex, and a second signal, provided by costimulatory molecules. The activation and expansion of CD4+ T cells is limited by the action of inhibitory molecules. Lectins may activate T cells, and Phytohemagglutinin (PHA) and Concanavalin A (ConA) are the best know examples. Furthermore, it is well characterized that the target for ConA recognition is localized in the TCR/CD3 complex. The present study was delineated to characterize the effects of the lectin ArtinM on murine CD4+ T cells and to investigate the possible mechanisms accounting for the observed effects. It was investigated the ArtinM direct effects on CD4+ T cells, concerning its ability to induce the production of cytokines, the expression of costimulatory and inhibitory molecules and cell differentiation. In addition, the possible surface receptors recognized by ArtinM and responsible for triggering cell activation were also assessed. Finally, signaling molecules involved in the direct effects of ArtinM were approached. The first evidence of direct interaction of ArtinM with CD4+ T cells was provided by cell agglutination. A dose-response curve has revealed that 5µg/ml was the best ArtinM concentration to achieve significant production of Th1 (IL-2 and IFN-?) and Th17 (IL-6 and IL-17A) cytokines by TCD4+ cells. Stimulus with the optimum ArtinM concentration has showed that after 12 hours incubation there was a significant augmentation of IL-2, IFN-?, IL- 6 and IL-17A levels in the cell supernatant; which has persisted in the course of 48 hours observation. The concomitant secretion of IFN-? and IL-17A led us to evaluate, by flow cytometry, the intracellular expression of these cytokines. After 24 hours stimulation with ArtinM, there was a significant increase in the frequency of cells IFN-?+IL-17+. Once the cytokines detection indicated that CD4+ T cells have been activated by ArtinM, the expression of CD25 and CTLA-4 molecules was assessed. ArtinM increased the expression of both molecules, in a dose-dependent manner. Interestingly, both cell surface molecules, CD25 and CTLA-4, were early and persistently detected a temporal pattern that is distinct from the provided by other inducers of CD4+ T cell activation. In order to determine the mechanism by which ArtinM acts on CD4+ T cells, potential targets of recognition were assessed: CD3??, CD3?, CD28, CD45 and CD4. These receptors were selected on the basis of prediction of N-glycosylation sites. Specific antibodies for these molecules were assayed regarding their ability to inhibit the ArtinM of inducing TCD4+ cells to produce cytokines, such as IL-2, IFN-?, IL-6 and IL-17A. Only anti-CD3 antibody was able to prevent the cytokines secretion induced by ArtinM. In addition, anti-CD3 antibody has inhibited the T CD4+ cell labeling by biotynil-ArtinM. These data indicate that ArtinM exerts its biological activity on T CD4+ cells through recognition of CD3 receptor ? chain glycans, without excluding the occurrence of ArtinM interactions with other glycoproteins on the surface of T CD4+ lymphocytes. The interaction of ArtinM with glycans at the surface of these cells was found to occur with great specificity, since high concentrations of the manotriose - Man? 1-3 [Man? 1-6] Man - were required to inhibit the binding. By using specific inhibitors of signaling molecules, we have found that PI3K, PTK and p42/44MAPK are relevant cytokine production profiles of Th1 and Th17 cells after stimulation with ArtinM. All toghether, these results indicate that ArtinM is a potent and rapid activator of CD4+ T cells. The activation induced by ArtinM is triggered by its binding to the CD3 receptor ? chain, which induces high expression of costimulator and inhibitory molecules. Moreover, it was demonstrated that ArtinM promotes the differentiation of naive CD4+ T cells into Th1 and Th17 cells by committing signaling molecules that are known as critical for the induction of cytokines that characterize these subpopulations of cells.

A lectina ArtinM, extraída de sementes de Artocarpus heterophyllus e caracterizada como um homotetrâmero constituído de subunidades de 16 kDa, tem alta afinidade de ligação a manotriose Man? 1-3 [Man? 1-6] Man, que constitui o core de N-glicanas. ArtinM é dotada de interessantes propriedades biológicas: (1) ativa neutrófilos a partir do reconhecimento de N-glicanas dos receptores CXCR2 e TLR2; (2) induz a desgranulação de mastócitos por interagir com N-glicanas de Fc?R ou com N-glicanas de IgE ligadas a Fc?R; (3) estimula a produção de IL-12, por reconhecer N-glicanas contidas no ectodomínio de TLR2 da superfície de células apresentadoras de antígeno (APCs); (4) exerce atividade imunomoduladora, que direciona o padrão de resposta para o perfil Th1; (5) confere resistência a infecções por patógenos intracelulares, como Paracoccidioides brasiliensis, Leishmania amazonensis e Leishmania major, Neospora caninum e Candida albicans Células T CD4+ participam de funções essenciais do sistema imune; durante o estabelecimento de uma resposta imune, podem ser desenvolvidas subpopulações de células T CD4+ adequadas para gerar respostas eficientes de combate a patógenos, manutenção da tolerância e regulação da imunidade. A ativação das células T CD4+ depende de um primeiro sinal, desencadeado pelo complexo TCR/CD3, e de um segundo sinal, oriundo de moléculas coestimulatórias como CD28. A ativação e expansão de células T CD4+ são limitadas pela ação de moléculas inibitórias, principalmente por CTLA-4. Lectinas podem ativar as células T, sendo a fitohemaglutinina (PHA) e a Concanavalin A (ConA) os exemplos mais conhecidos. Além disso, está bem caracterizado que o alvo de reconhecimento de ConA localiza-se no complexo TCR/CD3. No presente estudo buscou-se caracterizar os efeitos da lectina ArtinM sobre células T CD4+ murinas e investigar os possíveis mecanismos responsáveis pelos efeitos exercidos. Foram avaliados, inicialmente, os efeitos diretos de ArtinM sobre as células T CD4+, no que se refere à produção de citocinas, expressão de moléculas coestimulatórias e inibitórias e indução de diferenciação celular. Passou-se então à identificação de possíveis receptores de superfície reconhecidos por ArtinM e responsáveis pelo desencadeamento da ativação celular. Finalmente, buscou-se apontar moléculas sinalizadoras envolvidas nos efeitos diretos de ArtinM. A primeira evidência da interação direta de ArtinM com células T CD4+ foi proporcionada por aglutinação celular. Uma curva dose-resposta revelou que 5µg/ml foi a melhor concentração para adquirir significativa produção de citocinas Th1 (IL-2 e IFN-?) e Th17 (IL-6 e IL-17A) pelas células T CD4+. O estímulo com a concentração ótima de ArtinM mostrou que após 12 horas de incubação houve um significativo aumento nos níveis de IL-2, IFN-?, IL-6 e IL-17A no sobrenadante celular; persistindo no curso de 48 horas de observação. A secreção concomitante de IFN-? e IL-17A motivou a avaliação, por citometria de fluxo, da ocorrência de dupla marcação intracelular dessas citocinas. O estímulo, por 24 horas, com ArtinM, levou a importante aumento da frequência de células duplo-positivas para IFN-? e IL-17. Uma vez comprovado pelo padrão de citocinas secretadas que ArtinM promove a ativação das células T CD4+, investigou-se a expressão das moléculas CD25 e CTLA-4. ArtinM aumentou a expressão de ambas as moléculas, de maneira dose-dependente. Curiosamente, a detecção tanto de CD28, como de CTLA-4, foi precoce e persistente, diferindo do padrão temporal de expressão proporcionado por outros ativadores de células T CD4+. Com vistas a determinar o mecanismo através do qual ArtinM atua nas células T CD4+, alvos potenciais de reconhecimento foram ensaiados: CD3?, CD3??, CD28, CD45 e CD4. Esses receptores foram selecionados com base em predição de potenciais sítios Nglicosilados. Dessa forma, anticorpos específicos para essas moléculas foram utilizados para analisar a sua capacidade de inibir a atividade de ArtinM de induzir as células T CD4+ a produzir citocinas, como IL-2, IFN-?, IL-6 e IL-17A. Apenas o anticorpo anti-CD3?? foi capaz de impedir a secreção das citocinas induzidas por ArtinM. Além disso, esse anticorpo inibiu a marcação de células T CD4+ por ArtinM biotinilada. Esses dados indicam que ArtinM exerce sua atividade sobre células T CD4+ através do reconhecimento de glicanas na cadeia ? do receptor CD3, não excluindo-se, entretanto, a ocorrência da interação de ArtinM com outras glicoproteínas na superfície de linfócitos T CD4+. Também foi verificado que ArtinM possui alta especificidade por glicanas na superfície dessas células, pois foram necessárias elevadas concentrações de manotriose para inibir em 50% a ligação de ArtinM à superfície das células T CD4+. Através do uso de inibidores específicos para moléculas sinalizadoras, constatou-se que PI3K, PTK, p42/44MAPK, p38MAPK, JNK e PKC estão implicadas na sinalização para a produção das citocinas de perfis Th1 e Th17, induzida por ArtinM. Esse conjunto de resultados indica que ArtinM é um potente e rápido ativador de células T CD4+. A ativação celular induzida por ArtinM está relacionada com a ligação à cadeia ? do receptor CD3 e se associa à alta expressão de moléculas coestimuladoras e inibitórias. Ademais, demonstrou-se que ArtinM promove a diferenciação das células T CD4+ naive em células Th1 e Th17, utilizando moléculas sinalizadoras que são conhecidas como críticas para a indução de citocinas que caracterizam essas subpopulações celulares. / The lectin ArtinM, extracted from seeds of Artocarpus heterophyllus and characterized as a homotetramer consisted of 16 kDa subunits, has high binding affinity to the manotriose Man? 1-3 [Man? 1-6] Man, which is the core of N-glycans. ArtinM is endowed with interesting biological properties: (1) it activates neutrophils through the recognition of Nglycans attached to CXCR2 and TLR2 receptors; (2) induces degranulation of mast cells by interacting with N-glycans of Fc?R or to N-glycans of IgE bound to Fc?R; (3) stimulates the production of IL-12 through the recognition of N-glycans of the TLR2 ectodomain, expressed on the surface of antigen presenting cells (APCs); (4) exerts immunomodulatory activity, which accounts for Th1 immunity (5) confers resistance to intracellular pathogens, such as P. brasiliensis, Leishmania amazonensis and Leishmania major, Neospora caninum e Candida albicans. CD4+ T cells participate in essential functions of the immune system. During the development of an immune response, CD4+ T cells are activated and give origin to subpopulations of cells that are suitable for establishing effective responses to combat pathogens, for tolerance maintenance, and for adequate immuneregulation. The activation of CD4+ T cells depends on a first signal, triggered by the TCR/CD3 complex, and a second signal, provided by costimulatory molecules. The activation and expansion of CD4+ T cells is limited by the action of inhibitory molecules. Lectins may activate T cells, and Phytohemagglutinin (PHA) and Concanavalin A (ConA) are the best know examples. Furthermore, it is well characterized that the target for ConA recognition is localized in the TCR/CD3 complex. The present study was delineated to characterize the effects of the lectin ArtinM on murine CD4+ T cells and to investigate the possible mechanisms accounting for the observed effects. It was investigated the ArtinM direct effects on CD4+ T cells, concerning its ability to induce the production of cytokines, the expression of costimulatory and inhibitory molecules and cell differentiation. In addition, the possible surface receptors recognized by ArtinM and responsible for triggering cell activation were also assessed. Finally, signaling molecules involved in the direct effects of ArtinM were approached. The first evidence of direct interaction of ArtinM with CD4+ T cells was provided by cell agglutination. A dose-response curve has revealed that 5µg/ml was the best ArtinM concentration to achieve significant production of Th1 (IL-2 and IFN-?) and Th17 (IL-6 and IL-17A) cytokines by TCD4+ cells. Stimulus with the optimum ArtinM concentration has showed that after 12 hours incubation there was a significant augmentation of IL-2, IFN-?, IL- 6 and IL-17A levels in the cell supernatant; which has persisted in the course of 48 hours observation. The concomitant secretion of IFN-? and IL-17A led us to evaluate, by flow cytometry, the intracellular expression of these cytokines. After 24 hours stimulation with ArtinM, there was a significant increase in the frequency of cells IFN-?+IL-17+. Once the cytokines detection indicated that CD4+ T cells have been activated by ArtinM, the expression of CD25 and CTLA-4 molecules was assessed. ArtinM increased the expression of both molecules, in a dose-dependent manner. Interestingly, both cell surface molecules, CD25 and CTLA-4, were early and persistently detected a temporal pattern that is distinct from the provided by other inducers of CD4+ T cell activation. In order to determine the mechanism by which ArtinM acts on CD4+ T cells, potential targets of recognition were assessed: CD3??, CD3?, CD28, CD45 and CD4. These receptors were selected on the basis of prediction of N-glycosylation sites. Specific antibodies for these molecules were assayed regarding their ability to inhibit the ArtinM of inducing TCD4+ cells to produce cytokines, such as IL-2, IFN-?, IL-6 and IL-17A. Only anti-CD3 antibody was able to prevent the cytokines secretion induced by ArtinM. In addition, anti-CD3 antibody has inhibited the T CD4+ cell labeling by biotynil-ArtinM. These data indicate that ArtinM exerts its biological activity on T CD4+ cells through recognition of CD3 receptor ? chain glycans, without excluding the occurrence of ArtinM interactions with other glycoproteins on the surface of T CD4+ lymphocytes. The interaction of ArtinM with glycans at the surface of these cells was found to occur with great specificity, since high concentrations of the manotriose - Man? 1-3 [Man? 1-6] Man - were required to inhibit the binding. By using specific inhibitors of signaling molecules, we have found that PI3K, PTK and p42/44MAPK are relevant cytokine production profiles of Th1 and Th17 cells after stimulation with ArtinM. All toghether, these results indicate that ArtinM is a potent and rapid activator of CD4+ T cells. The activation induced by ArtinM is triggered by its binding to the CD3 receptor ? chain, which induces high expression of costimulator and inhibitory molecules. Moreover, it was demonstrated that ArtinM promotes the differentiation of naive CD4+ T cells into Th1 and Th17 cells by committing signaling molecules that are known as critical for the induction of cytokines that characterize these subpopulations of cells.

Solid organ transplantation is now an established and effective treatment option for end-stage organ failure. Whilst early outcomes have improved significantly over recent decades, longer-term outcomes have changed little. Despite advances in immunosuppression, most transplanted organs suffer an inevitable decline in function attributed to chronic rejection. It is evident that the alloimmune response remains incompletely characterised. Crucially, despite description several decades ago, the precise contribution that the direct (recognition of intact allogeneic MHC) and indirect (recognition of self-MHC restricted allopeptide) pathways make to allograft rejection remains incompletely understood. In this thesis, murine models of heterotopic cardiac transplantation have been utilised to analyse these pathways. The key findings of this work are as follows: 1) If able to evade NK cell killing, passenger donor CD4 T cells can make cognate, direct-pathway, interactions with recipient B cells. This interaction results in augmentation of all arms of the alloimmune response and acceleration of allograft rejection. 2) Direct-pathway CD4 T cell allorecognition is restricted to the immediate post transplantation period. Donor APCs are the major source of MHC class II for direct-pathway priming, and these are cleared rapidly by both innate and adaptive responses of the recipient, effectively limiting the longevity of direct allorecognition. 3) The duration of indirect-pathway responses against different alloantigens is variable, limited by availability of donor antigen. Expression of donor MHC class II is restricted to APCs and possibly endothelium (where expression is transient) limiting the duration of indirect-pathway allorecognition against MHC class II alloantigen. Indirect-pathway CD4 T cell responses targeted against parenchymal alloantigen are long-lived, and can provide help for generating alloantibody against different MHC alloantigens. 4) In response to continual presentation of target epitope indirect-pathway CD4 T cell responses against parenchymal expressed alloantigen are long-lived. The continual division of these cells results in greatly increased numbers of alloantigen-specific CD4 T cells in the chronic phase of the response, but despite this, memory responses are impaired. 5) Generating indirect-pathway regulatory T cells specific for parenchymal expressed alloantigen appears to be the most effective strategy to ameliorating chronic rejection.

Indiana University-Purdue University Indianapolis (IUPUI) / Facial nerve axotomy (FNA) in immunodeficient mice causes significantly more facial motoneuron (FMN) loss relative to wild type (WT), indicating that the immune system is neuroprotective. Further studies reveal that both CD4+ T cells and interleukin 10 (IL-10) act centrally to promote neuronal survival after injury. This study first investigated the roles of IL-10 and CD4+ T cells in neuroprotection after axotomy. CD4+ T cell-mediated neuroprotection requires centrally-produced IL-10, but the source of IL-10 is unknown. Using FNA on IL-10 reporter mice, immunohistochemistry was employed to identify the IL-10 source. Unexpectedly, axotomy induced astrocyte production of IL-10. To test if microglia- or astrocyte-specific IL-10 is needed for neuroprotection, cell-specific conditional knockout mice were generated. Neither knockout scenario affected FMN survival after FNA, suggesting that coordinated IL-10 production by both glia contributes to neuroprotection. The effect of immune status on the post-FNA molecular response was studied to characterize CD4+ T cell-mediated neuroprotection. In the recombinase-activating gene2 knockout (RAG-2-/-) mouse model of immunodeficiency, glial microenvironment responses were significantly impaired. Reconstitution with CD4+ T cells restored glial activation to normal levels. Motoneuron regeneration responses remained unaffected by immune status. These findings indicate that CD4+ T cell-mediated neuroprotection after injury occurs indirectly via microenvironment regulation. Immunodysregulation is evident in amyotrophic lateral sclerosis (ALS), and FMN survival after FNA is worse in the mutant superoxide dismutase (mSOD1) mouse model of ALS. Further experiments reveal that mSOD1 CD4+ T cells are neuroprotective in RAG-2-/- mice, whereas mSOD1 whole splenocytes (WS) are not. The third aim examined if the mSOD1 WS environment inhibits mSOD1 CD4+ T cell glial regulation after axotomy. Unexpectedly, both treatments were equally effective in promoting glial activation. Instead, mSOD1 WS treatment induced a motoneuron-specific death mechanism prevalent in ALS. In conclusion, the peripheral immune system regulates the central glial microenvironment utilizing IL-10 to promote neuronal survival after axotomy. Astrocytes, specifically, may be responsible for transducing peripheral immune signals into microenvironment regulation. Additionally, the immune system in ALS may directly participate in disease pathology.

京都大学 / 0048 / 新制・論文博士 / 博士(医学) / 乙第13160号 / 論医博第2147号 / 新制||医||1029(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 生田 宏一, 教授 杉田 昌彦, 教授 椛島 健治 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

<p>E and Id proteins are members of the basic helix-loop-helix (bHLH) transcription regulator family. These proteins control a broad range of lymphocyte biology, from the development of multiple lineages to execution of their effector functions. With the development of new experiment models, novel functions of E and Id proteins continued to be discovered. In this thesis, I focused my study on the role of Id2 in gamma delta T cells and CD4<super>+</super> alpha beta T cells, as well as the role of Id3 in B cells.</p><p> Id proteins have been shown to control gamma delta T cell development. Id3 knockout mice demonstrate a dramatic expansion of innate-like Vgamma1.1<super>+</super> Vdelta6.3<super>+</super> T cells in the neonatal stage, suggesting that Id3 is an inhibitor of their development. Interestingly, Id3 knockout mice with a B6/129 mix background have much less expansion of the Vgamma1.1<super>+</super> Vdelta6.3<super>+</super> T cells compared to mice with pure B6 background. Genetic studies showed that this difference is strongly influences by a chromosome region very close to the Id2 locus. Using the Id2<super>f/f</super> CD4Cre<super>+</super> mice, I found that Id2 is also an inhibitor of gamma delta T cell development. Deletion of Id2 alone is sufficient to enhance the maturation of these cells in the thymus and induce a moderate expansion of gamma delta T cells in the periphery. This study demonstrated the delicate balance of transcription control in cells of the immune system.</p><p> The Id2<super>f/f</super> CD4Cre<super>+</super> mice also enabled me to study the role of Id2 in peripheral CD4<super>+</super> alpha beta T cell functions, which was difficult in the past because Id2 knockout mice lack lymph node development. I found that CD4 T cells in these mice have a profound defect in mounting immune responses, demonstrated by a complete resistance to induction of experimental autoimmune encephalomyelitis (EAE). I found that Id2-deficient CD4 T cells fail to infiltrate the central nervous system, and the effector CD4 T cell population is smaller compared to that in control mice. Id2 is important for the survival and proliferation of effector CD4 T cells, and this phenotype was correlated with an increased expression of <italic>Bim</italic> and <italic>SOCS3</italic>. This study revealed a novel role of Id2 in the functioning of CD4<super>+ </super>alpha beta T cells.</p><p> Switching my focus to B cells, recent next generation sequencing of human Burkitt lymphoma samples revealed that a significant proportion of them have mutations of Id3. This finding suggests that Id3 may be a tumor suppressor gene in the lymphoid system. Utilizing various Id3 knockout and conditional knockout mouse models, I showed that Id3 deficiency can accelerate lymphoid tumor genesis driven by the over-expression of oncogene c-Myc. This work may lead to development of a more realistic mouse model of human Burkitt lymphoma, allowing more mechanistic studies and perhaps preclinical tests of new therapies.</p> / Dissertation

<p>Helminth exposure, allergy and asthma each induce cellular responses in lymphoid and peripheral tissues that give rise to type-2 inflammation. Essential molecular mediators of this response are type-2 cytokines interleukin(IL)-4 and IL-13 derived from various subsets of immune cells. In lymphoid tissues, CD4+ Tfh cells make IL-4 to elicit IgE and high-affinity IgG1 production. In peripheral sites of infection, group 2 innate lymphoid (ILC2) cells make IL-13 and Th2 cells make both IL-13 and IL-4. Together, these cells mediate smooth muscle contraction, mucus production and recruitment of other innate effector cells, all of which are hallmarks of type-2 inflammation. As central mediators of type-2 inflammation, understanding the cell-specific expression and molecular regulation of type-2 cytokines in CD4+ T cells and ILC2 cells may lead to new therapies that ameliorate allergic disease and helminth infections. </p><p>The AP-1 factor basic leucine zipper transcription factor ATF-like (BATF) has been identified as a pioneer factor in in vitro-generated Th17 cells. BATF facilitates chromatin remodeling at the IL-17 locus as well as loci of key Th17-associated lineage specifying factors. It has also been deemed essential to the generation of functional humoral immunity through the development of follicular helper T (Tfh) cells and germinal center B cells. However, the role of BATF in the development and function of other CD4+ T helper subsets and innate immune cells in vivo has remained unclear. I show here that mice deficient in BATF do not develop type-2 inflammation after exposure to the parasitic helminth Nippostongylus brasiliensis. Since type-2 cytokine expression by Th2 and ILC2 cells is essential for expedient helminth expulsion, I hypothesized that BATF likely has a role in the development and/or induction of cytokine expression in CD4+ Th2 cells and ILC2 cells. Consistent with this hypothesis, I found that BATF utilizes a novel mechanism to control Th2 cytokine expression in Th2 cells. Specifically, BATF promotes permissive epigenetic modifications to alter the chromatin landscape early during Th2 cell differentiation. In addition, my data show that BATF deficiency inhibits the activation of ILC2 cells, preventing ILC2-mediated helminth clearance. </p><p>In addition to uncovering BATF-mediated regulations of type-2 inflammation, my work has revealed new insight into the role of a second bZIP transcription factor, cMaf, during type-2 immunity. As mentioned above, helminth exposure elicits IL-4 production by both CD4+ Tfh and Th2 cells. Although type-2 cytokine transcription has been well characterized in Th2 cells, Tfh cell-mediated IL-4 production has yet to be fully defined. Importantly, I show that IL-4 production by Tfh cells is sustained upon deletion of classical IL-4 regulatory factors signal transducer and activator of transcription 6 (STAT6) and STAT5 and is not dependent on high GATA-3 expression. In sum, Tfh-driven IL-4 production is induced independent of classical pathways in Th2 cells. </p><p>Presently, the non-canonical transcription factors involved in IL-4 production by Tfh cells remain unclear. C-Maf works with BCL6, the master regulator of Tfh cells, to elicit Tfh formation. However, the precise role of c-Maf in Tfh cell fate and function remains unclear. So far, it has been shown that in Th2 cells, c-Maf binds to the IL-4 promoter and in Tfh cells, c-Maf binds to the CNS2 enhancer of the IL-4 locus to regulate IL-4 expression. Therefore, I hypothesized that c-Maf is important in non-canonical, GATA-3-independent IL-4 production by Tfh cells. </p><p>Here, I show that Tfh cells lacking canonical Th2 pathways for IL-4 expression express high levels of c-Maf and IL-4 transcript. Deletion of c-Maf in CD4+ T cells resulted in normal induction of BCL6 expression. Thus the initial stages of Tfh cell generation were induced. However, cMaf-deficient CD4+ T cells did not express important molecules associated with Tfh cell migration. Immunohistochemistry also confirmed that c-Maf deficiency inhibited CD4+ T cell migration from the paracortex into the B cell follicle. </p><p>These defects did not inhibit cMaf-deficient CD4+ T cells from making IL-4 transcript; however, IL-4 protein production was significantly impaired. Together, these results demonstrate that c-Maf is essential for Tfh cell-mediated immunity by promoting CD4+ T cell migration to the B cell follicles and the production of IL-4 protein in the germinal centers. </p><p>Collectively, the objective of my thesis research is to define the roles of the bZIP transcription factors BATF and c-Maf in type-2 inflammation. My data demonstrate that BATF is essential for the differentiation and function of Tfh, Th2, and ILC2 cells during helminth infection. Additionally, I have shown that c-Maf is required for Tfh function and CD4+ T cell migration to the B cell follicle. Thus, BATF and c-Maf are central to the development of humoral and peripheral type-2 inflammatory responses against helminth infection. Given the wide spectrum of disorders associated with type-2 inflammation, the identification of factors relevant to the development and function of Th2-, ILC2- and Tfh-driven allergic pathologies is broadly relevant. A comprehensive characterization of core factors like BATF and c-Maf provide new avenues in which to explore novel therapies to modulate type-2 inflammatory responses.</p> / Dissertation

<p>CD4+ T cells play a crucial in the adaptive immune system. They function as the central hub to orchestrate the rest of immunity: CD4+ T cells are essential governing machinery in antibacterial and antiviral responses by facilitating B cell affinity maturation and coordinating the innate and adaptive immune systems to boost the overall immune outcome; on the contrary, hyperactivation of the inflammatory lineages of CD4+ T cells, as well as the impairments of suppressive CD4+ regulatory T cells, are the etiology of various autoimmunity and inflammatory diseases. The broad role of CD4+ T cells in both physiological and pathological contexts prompted me to explore the modulation of CD4+ T cells on the molecular level.</p><p>microRNAs (miRNAs) are small RNA molecules capable of regulating gene expression post-transcriptionally. miRNAs have been shown to exert substantial regulatory effects on CD4+ T cell activation, differentiation and helper function. Specifically, my lab has previously established the function of the miR-17-92 cluster in Th1 differentiation and anti-tumor responses. Here, I further analyzed the role of this miRNA cluster in Th17 differentiation, specifically, in the context of autoimmune diseases. Using both gain- and loss-of-function approaches, I demonstrated that miRNAs in miR-17-92, specifically, miR-17 and miR-19b in this cluster, is a crucial promoter of Th17 differentiation. Consequently, loss of miR-17-92 expression in T cells mitigated the progression of experimental autoimmune encephalomyelitis and T cell-induced colitis. In combination with my previous data, the molecular dissection of this cluster establishes that miR-19b and miR-17 play a comprehensive role in promoting multiple aspects of inflammatory T cell responses, which underscore them as potential targets for oligonucleotide-based therapy in treating autoimmune diseases. </p><p>To systematically study miRNA regulation in effector CD4+ T cells, I devised a large-scale miRNAome profiling to track in vivo miRNA changes in antigen-specific CD4+ T cells activated by Listeria challenge. From this screening, I identified that miR-23a expression tightly correlates with CD4+ effector expansion. Ectopic expression and genetic deletion strategies validated that miR-23a was required for antigen-stimulated effector CD4+ T cell survival in vitro and in vivo. I further determined that miR-23a targets Ppif, a gatekeeper of mitochondrial reactive oxygen species (ROS) release that protects CD4+ T cells from necrosis. Necrosis is a type of cell death that provokes inflammation, and it is prominently triggered by ROS release and its consequent oxidative stress. My finding that miR-23a curbs ROS-mediated necrosis highlights the essential role of this miRNA in maintaining immune homeostasis. </p><p>A key feature of miRNAs is their ability to modulate different biological aspects in different cell populations. Previously, my lab found that miR-23a potently suppresses CD8+ T cell cytotoxicity by restricting BLIMP1 expression. Since BLIMP1 has been found to inhibit T follicular helper (Tfh) differentiation by antagonizing the master transcription factor BCL6, I investigated whether miR-23a is also involved in Tfh differentiation. However, I found that miR-23a does not target BLIMP1 in CD4+ T cells and loss of miR-23a even fostered Tfh differentiation. This data indicate that miR-23a may target other pathways in CD4+ T cells regarding the Tfh differentiation pathway.</p><p>Although the lineage identity and regulatory networks for Tfh cells have been defined, the differentiation path of Tfh cells remains elusive. Two models have been proposed to explain the differentiation process of Tfh cells: in the parallel differentiation model, the Tfh lineage is segregated from other effector lineages at the early stage of antigen activation; alternatively, the sequential differentiation model suggests that naïve CD4+ T cells first differentiate into various effector lineages, then further program into Tfh cells. To address this question, I developed a novel in vitro co-culture system that employed antigen-specific CD4+ T cells, naïve B cells presenting cognate T cell antigen and BAFF-producing feeder cells to mimic germinal center. Using this system, I were able to robustly generate GC-like B cells. Notably, well-differentiated Th1 or Th2 effector cells also quickly acquired Tfh phenotype and function during in vitro co-culture, which suggested a sequential differentiation path for Tfh cells. To examine this path in vivo, under conditions of classical Th1- or Th2-type immunizations, I employed a TCRβ repertoire sequencing technique to track the clonotype origin of Tfh cells. Under both Th1- and Th2- immunization conditions, I observed profound repertoire overlaps between the Teff and Tfh populations, which strongly supports the proposed sequential differentiation model. Therefore, my studies establish a new platform to conveniently study Tfh-GC B cell interactions and provide insights into Tfh differentiation processes.</p> / Dissertation

As infecções humanas com a filaria Mansonella ozzardi ocorrem em focos situados em regiões tropicais e subtropicais da América Central e do Sul e frequentemente coexistem com outras doenças endêmicas tropicais. Na Amazônia brasileira, as infecções são geralmente assintomáticas e a maior parte delas, consequentemente, deixam de ser diagnosticada. As filarioses crônicas, geralmente não tratadas, podem criar um ambiente imunorregulador, caracterizado pela expansão de linfócitos T produtores de IL-10, que mediam a supressão de respostas proliferativas de células T frente a antígenos específicos bem como a antígenos não-relacionados. Neste trabalho, utilizamos marcadores de ativação celular (CD69 e HLA-DR) e de atividade reguladora (CD39, CTLA-4, OX40, GITR, LAG3, PD-1, LAP-TGF-&#946; e TNFRII) para caracterizar populações de células mononucleares de sangue periférico (PBMCs) em indivíduos infectados por M. ozzardi bem como em controles saudáveis de uma área endêmica deste parasito na Amazônia Brasileira. A análise de PBMCs, por citometria de fluxo multiparamétrica de 49 pacientes infectados por M. ozzardi, mostrou que pacientes e controles apresentam proporções similares de Treg clássicas circulantes, no entanto, indivíduos infectados apresentam um aumento da proporção de células CD4+ e células T reguladoras (Tregs) que expressam a molécula CD39. Células Treg CD39+ parecem definir uma população distinta entre as Treg, pois ao compararmos os marcadores de regulação e ativação entre Tregs CD39+ e CD39- encontramos proporções aumentas destes marcadores nas Treg CD39+. O bloqueio dessa molécula em condições de reestimulo celular aumenta a produção de citocinas inflamatórias e diminui a produção de IL-10 confirmando seu papel regulador. / Human infections with the filarial parasite Mansonella ozzardi are common in areas of tropical and subtropical Central and South America and often coexist with other endemic tropical diseases, such as malaria. In the Amazonian Basin of Brazil, infections are typically asymptomatic; most of them will remain undiagnosed. These chronic, untreated filarial infections are potentially associated with a regulatory immune environment, dominated by IL-10-producing T-cells, which mediate the suppression of T-cell proliferation in response to filarial and non-related antigens. Here, we used markers of cell activation (CD69 and HLA-DR) and regulatory activity (CD39, CTLA-4, OX40, GITR, and TNFRII) to characterize peripheral-blood mononuclear cell (PBMCs) subpopulations in individuals infected with |M. ozzardi and in healthy controls living in an area of M. ozzardi endemicity in the Brazilian Amazon. Multiparameter flow cytometry analysis of PBMCs from 49 malaria patients showed that patients and controls have similar proportions of classic circulating Tregs, however, the proportion of CD4 + cells and Tregs expressing the CD39 (an ectonucleotidase that regulates the balance of immune responses through Phosphohydrolysis of ATP, an inflammatory molecule in adenosine, an anti-inflammatory molecule), is increased in infected patients. CD39+Treg cells seem to define a distinct population among Tregs, compare activation and regulatory markers between CD39+ and CD39- Tregs - we found increased proportions of these markers in the CD39+ Tregs. Blocking this molecule under cellular restimulation conditions increases production of inflammatory cytokines and decreases IL-10 production, improving its regulatory role.

Self-reactive CD4+ helper T cells (Th) are key causal agents in the pathogenesis of many autoimmune diseases. Experimental autoimmune encephalomyelitis (EAE) is a CD4+T cell model of the demyelinating autoimmune disease multiple sclerosis (MS). It has been shown that EAE is caused by CD4+ T-cells that produce pro-inflammatory cytokines IFN-γ (Th1) and IL-17 (Th17). As such, understanding how these Th cells are generated and controlled is essential. There is debate as to whether Th1 and Th17 cells act independently in EAE or if there is plasticity between these two subtypes, and whether the capacity to switch from Th1 to Th17 confers pathogenic capacity. T-bet was first described as the master transcription factor for Th1 cells, and is thought to have a critical role in EAE even though IFN-γ, the Th1 archetypal cytokine, has been shown to be redundant. More recent work has shown that T-bet is expressed in multiple immune cell types, and it remains unclear in what cells the expression of T-bet is required for EAE. Considerable efforts have been put into understanding the role of T-bet in EAE pathogenesis, with a view to modulate cells expressing T-bet for therapy. The hypothesis of this work was that T-bet has multifaceted roles in EAE, in initiating and directing an immune response in innate antigen presenting cells such as dendritic cells (DC) as well as programming pathogenic effector CD4+ T cell (Teff) response to antigen. T-bet-/- mice were studied using different models of EAE to dissect the role of T-bet in disease pathogenesis. Active immunisation of C57BL/6 mice with the immunodominant peptide from myelin oligodendrocyte glycoprotein (MOG35-55) showed that T-bet-/- mice developed EAE with an IL-17 dominated profile and critically, T-bet-/- mice were able to produce GM-CSF which has recently been described as a key cytokine for EAE. T-bet-/- cells were not able to transfer EAE in a model of passive transfer EAE, where CD4+ T cells were polarised towards a Th1 profile in vitro. Illustrating that T-bet is required in CD4+ T cells for Th1 mediated EAE. DC driven EAE showed that T-bet-/- DC were able to activate CD4+ T cells in vitro and cause EAE upon co-transfer into host mice with transgenic CD4+ T cells. Thus, it has been shown that T-bet is not required in EAE. This work represents a step further towards understanding the disease mechanisms involved in EAE and suggests T-bet is not an appropriate therapeutic target for the treatment of MS.